Compare Danaher Corporation (DHR) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Li Auto Inc — how do they compare? Danaher Corporation trades at $205.66 (market cap $145.83B), while Li Auto Inc trades at $12.51 (market cap $12.28B). The key difference: Danaher Corporation is far larger — about 11.9× Li Auto Inc's market cap, and Danaher Corporation pays a 0.77% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals.
| DHR | LI | |
|---|---|---|
Market Cap | $145.83B | $12.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $26.69 |
52-Week Low | $161.91 | $11.74 |
Enterprise Value | $168.04B | $1.11B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Li Auto (LI) trades at $12.84, down 0.85% on the day, with bearish technical signals and mixed earnings performance. The company reported declining revenue from $144.5B in 2024 to $112.3B in 2025, with net income dropping to $1.12B. Recent vehicle launches including the Li L6 and L8 aim to boost deliveries amid intense Chinese EV competition.
While analyst consensus suggests moderate upside to $14.80 price target, significant risks include declining profitability, negative cash flow trends, and competitive pressures in China's EV market. The stock faces headwinds from execution challenges and macroeconomic uncertainties affecting the auto sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
